28 Jun Notch Therapeutics
David Main, President and CEO
April 12 | 2:30pm | Dark Horse Consulting Ballroom
Notch is developing renewable, induced pluripotent stem cell (iPSC)-derived immunotherapies, initially targeting cancer, where cell therapies offer transformational benefits over existing standards of care. Driven to enhance patient outcomes, we are working to maximize the benefit of cell therapies through a proprietary T cell-production platform that combines sophisticated product design with commercially compatible processes. Our platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies and delivers the ability to design and manufacture a uniform and unlimited supply of therapeutic T cells. Located in three cell-therapy centers of excellence in Vancouver, Toronto, and Seattle, our team comprises some of the best minds in preclinical science, advanced cell manufacturing, bioengineering, and systems biology.